S-1: Nuwellis, Inc. Files S-1 for Public Offering Amidst Going Concern Doubts and Potential Acquisition

Nuwellis, Inc. has filed an S-1 registration statement to offer common stock and warrants, aiming to raise approximately $4.2 million for working capital and potential acquisition activities, despite ongoing operating losses and substantial doubt about its ability to continue as a going concern.

Summary

• Nuwellis, Inc. is a commercial-stage medical technology company focused on ultrafiltration therapy, primarily with its Aquadex SmartFlow systems.
• The company is offering 5,387,931 shares of common stock, pre-funded warrants for up to 5,387,931 shares, Series A Warrants for up to 10,775,862 shares, and Series B Warrants for up to 5,387,931 shares.
• The assumed combined public offering price is $0.928 per share of common stock and accompanying common warrants, based on the May 23, 2025 Nasdaq closing price.
• Pre-funded warrants have an exercise price of $0.0001 per share, and Series B Warrants include a zero cash exercise option, meaning nominal or no additional funds are expected from their exercise.
• The offering is expected to generate net proceeds of approximately $4.2 million, or $4.9 million if the underwriters' over-allotment option is fully exercised.
• Proceeds are intended for working capital and general corporate purposes, including potential acquisition activity, such as a possible bid for Arch Therapeutics, Inc.'s assets.
• The company reported a net loss of $3.0 million for the three months ended March 31, 2025, and an accumulated deficit of $301.8 million as of the same date.
• Nuwellis's ten largest customers accounted for 57.9% of revenues for the three months ended March 31, 2025, with the largest customer representing 13.7%.

Sentiment

Score: 3

Explanation: The document outlines a significant capital raise, which is positive for liquidity, but it is necessitated by substantial ongoing operating losses and a 'going concern' doubt. The offering itself is highly dilutive, and the company faces numerous operational, regulatory, and market risks, including a recent Class 1 product recall and expiring key patents. The overall financial health and future prospects, as presented, are challenging.

Positives

• The Aquadex SmartFlow system received 510(k) clearance in February 2020 to include pediatric patients weighing 20kg or more, expanding commercialization efforts into pediatrics.
• A new and dedicated Category III CPT code, 0692T, became effective on January 1, 2022, for Therapeutic Ultrafiltration, providing additional reimbursement for outpatient ultrafiltration.
• The company has regained compliance with Nasdaq's Minimum Bid Price Requirement and Stockholders Equity Requirement as of December 17, 2024.

Negatives

• The company has incurred operating losses since its inception, including a net loss of $3.0 million for the three months ended March 31, 2025, and an accumulated deficit of $301.8 million.
• There is substantial doubt about the company's ability to continue as a going concern through the next twelve months, necessitating additional capital.
• A material weakness in internal control over financial reporting was identified as of December 31, 2024, due to insufficient headcount for segregation of duties and lack of contemporaneous documentation.
• The company's near-term prospects are highly dependent on revenues from a single product, the Aquadex System, and faces significant challenges in expanding its market acceptance.
• Nuwellis has limited commercial manufacturing experience and depends on third-party and single-source suppliers, making it vulnerable to supply problems and price fluctuations.
• The company voluntarily recalled specific lots of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit on December 11, 2024, due to 'Ultrafiltrate Weight Mismatch' or 'Excessive Weight Mismatch' alarms, with five reported incidences, three leading to patient dehydration.
• The patents licensed from Baxter, crucial for the Aquadex Business, are estimated to expire by mid-2025.

Risks

• The company's ability to continue as a going concern is in substantial doubt, requiring additional capital that may not be available on favorable terms or at all.
• Failure to remediate the identified material weakness in internal control over financial reporting could adversely affect business, reputation, and stock price.
• Nasdaq may delist the common stock due to non-compliance with listing requirements, including the minimum bid price and stockholders' equity, or due to public interest concerns related to dilutive warrant terms.
• Sales of a substantial number of shares by existing stockholders, including those from preferred stock and warrants, could cause the stock price to fall and result in significant dilution.
• High dependence on a single product (Aquadex System) and challenges in expanding its market acceptance could adversely affect sales and profitability.
• Reliance on a limited number of customers (top 10 customers accounted for 57.9% of Q1 2025 revenues) poses a risk if any major customer reduces purchases or discontinues product use.
• Limited commercial manufacturing experience and dependence on third-party/single-source suppliers could lead to production difficulties, delays, or increased costs.
• Inability to develop adequate distribution, customer service, and technical support networks could hinder effective marketing and sales.
• Intense competition from other medical device, pharmaceutical, and gene/cell therapy companies, some with greater resources, may prevent market penetration.
• Significant governmental regulation and changes in healthcare laws (e.g., Affordable Care Act, reimbursement policies) could adversely affect sales and operations.
• Product defects, such as the recent Class 1 recall of the AquaFlexFlow UF 500 Plus, could lead to product liability lawsuits, significant costs, negative publicity, and reduced demand.
• Violation of Federal Food, Drug, and Cosmetic Act (FDCA) or other statutes could result in enforcement actions, fines, recalls, or suspension of production.
• Risks associated with international operations include currency fluctuations, difficulties in enforcing receivables, political instability, longer payment cycles, additional taxes, import restrictions, and compliance with regulations like EU MDR.
• Failure to protect intellectual property rights, including expiring patents and potential infringement claims, could adversely affect business and financial condition.
• Security breaches, data loss, and other disruptions to IT systems could compromise sensitive information and expose the company to liability.
• The rights of common stockholders could be adversely affected by the rights of holders of outstanding preferred stock and future stock issuances.
• Future acquisitions, such as the potential bid for Arch Therapeutics assets, carry risks of integration difficulties, impairment charges, and further dilution.
• Failure to comply with federal and state laws regarding off-label use of products could lead to substantial civil and criminal penalties and harm reputation.
• Changes in U.S. federal government funding for the FDA and other agencies could hinder their ability to review and approve new products, impacting the company's business.

Future Outlook

The company anticipates continued operating losses in the near-term as it invests in expanding sales and marketing capabilities, manufacturing components, and complying with public company requirements. It expects to need additional capital to fund operations through the end of fiscal year 2025. The company intends to complete MDR certification and CE Mark under EU MDR prior to the extended deadline of December 31, 2028. The company will consider submitting a bid for Arch Therapeutics' assets if sufficient funds are raised from this offering or other sources.

Management Comments

• Management believes that the Aquadex System may offer hospitals an economic benefit for regular in-patient or out-patient usage to avoid readmissions for heart failure.
• Management is taking steps to remediate material weaknesses in internal control over financial reporting as soon as possible, subject to limitations on liquidity that may prevent or delay additional hirings.
• Management will have broad discretion over the uses of the net proceeds from this offering, and investors will be relying on their judgment regarding the application of the proceeds.

Industry Context

Nuwellis operates in the medical technology sector, specifically focusing on ultrafiltration therapy for fluid overload. Its primary product, the Aquadex System, competes indirectly with pharmacological treatments like diuretics, which are the standard of care, and other filter-based devices like Baxter's Prismaflex and Medtronic's Carpe Diem system. The industry is subject to intense competition, significant governmental regulation, and evolving healthcare reforms, including changes in reimbursement policies and fraud and abuse laws. The company's consideration of acquiring Arch Therapeutics, a biotechnology company, suggests a potential diversification or expansion within the broader healthcare and medical device industry.

Comparison to Industry Standards

• The Aquadex System competes against pharmacological treatment (diuretics) as the standard of care for fluid overload, with no direct competitors in heart failure or critical care in the U.S.
• Indirect competitors include Baxter's Prismaflex, approved for continuous renal replacement therapy for patients weighing 20kg or more, and Medtronic's Carpe Diem system, indicated for acute kidney injury or fluid overloaded patients requiring hemodialysis or hemofiltration therapy.
• Baxter's HF20 Set is authorized under an Emergency Use Authorization for CRRT in low-weight patients (8-20 kg) during the COVID-19 pandemic, which is a specific niche compared to Aquadex's broader indication.

Management Changes

Corporate Governance

Legal Proceedings

• Arch Therapeutics, Inc., a potential acquisition target, filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on April 18, 2025.
• On December 11, 2024, the company initiated a voluntary Class 1 recall of specific lots of the AquaFlexFlow UF 500 Plus extracorporeal blood circuit due to 'Ultrafiltrate Weight Mismatch' or 'Excessive Weight Mismatch' alarms, with five reported incidences, three leading to patient dehydration.

Related Party Transactions

• The selling securityholders in the July 2024 Offering were granted a right of participation for 12 months following the closing to participate in future equity issuances for cash consideration, up to 40% of the subsequent financing on the same terms.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution from the offering, and face potential further dilution from the exercise of outstanding preferred stock, warrants, and options.
• Shareholders are exposed to the risk of Nasdaq delisting, which could limit liquidity and increase volatility of the common stock.
• Customers may experience product delivery delays due to manufacturing or supply chain issues, and the recent Class 1 recall could impact product availability and trust.
• Employees may be affected by the identified material weakness in internal controls related to insufficient headcount, potentially impacting workload and operational efficiency.

Next Steps

• The company will hold a meeting to obtain Warrant Stockholder Approval as soon as practicable following the closing of this offering, but no later than sixty days following the closing, and further agreed to cause an additional stockholder meeting to be held every forty days thereafter until such approval is obtained.
• The company intends to complete MDR certification and CE Mark under EU MDR prior to the extended deadline of December 31, 2028.
• The company will consider submitting a bid for substantially all the assets of Arch Therapeutics, Inc. by June 20, 2025, if sufficient funds are raised.
• The company is taking steps to remediate identified material weaknesses in internal control over financial reporting.
• The company will be subject to a Nasdaq Mandatory Panel Monitor for one year from December 17, 2024, regarding compliance with the Stockholders Equity Requirement.

Key Dates

Keywords

Medical Technology, Ultrafiltration, Aquadex SmartFlow, SEC Filing, S-1 Registration, Public Offering, Common Stock, Warrants, Pre-funded Warrants, Series A Warrants, Series B Warrants, Capital Raise, Dilution, Going Concern, Operating Losses, Accumulated Deficit, Nasdaq Listing, Delisting Risk, Internal Controls, Product Recall, Medical Devices, Fluid Overload, Heart Failure, Critical Care, Pediatrics, Intellectual Property, Healthcare Regulation, FDA, Chapter 11, Acquisition